LinkedIn Icon Twitter Icon
March 19-21, 2018 | Boston, MA

 

Day One
Tuesday, March 20 2018

Day Two
Wednesday, March 21 2018

08.25
Chair’s Opening Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center

08.30
Keynote: Investigating Crucial Factors That Determine the Success of Immune Checkpoint Combinations

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center

Synopsis

  • Understanding the importance of sequencing and timing in the administration of combination therapies to maximize efficacy
  • Investigating the most effective approaches to identify truly translational biomarkers to identify patients for checkpoint monotherapy and combination trials
  • Appreciating the true potential of immuno-oncology: what does the future hold for the field and how can we work most effectively to realise this potential

09.00
Defining the Treatment Duration of Checkpoint Blockade

  • Israel Lowy VP, Clinical Sciences & Head of Translational Oncology , Regeneron

Synopsis

  • Understanding the factors that have influenced the typical dosing plan for PD-1/PD-L1 blockade
  • How can the duration of treatment administration be optimized and what does optimization actually mean?
  • Criteria that need to be taken into account when discussing treatment duration in the context of current immunotherapies

09.30
Keynote Panel Discussion: Dissecting Recent Clinical Successes and Failures to Give Greater Clarity Moving Forward

Synopsis

  • Assessing the relative contributions of the molecule, patient population and endpoint selection to final result
  • Discussing the ways in which recent clinical results have impacted the field and how priorities and practices will change in the near future as a result
  • How will the recent CAR-T approval impact on the use of checkpoint modulators?
  • Understanding the latest monotherapy data and how this will impact the field

10.00
Morning Refreshments & Networking

Bridging the Translational ‘Valley of Death’ Through Clinically Relevant Preclinical Models

11.00 Modelling the Holistic Tumor Microenvironment in Preclinical Models

  • Understanding the potential of humanized and syngeneic models in recapitulating the tumor micro-environment
  • Generating humanized systems to validate targets in the myeloid compartment
  • Exploring approaches to analyze MDSCs in humanized PDx models

Corinne Reimer, Associate Director, In Vivo Pharmacology, AstraZeneca

11.30 Preclinical Approaches to Model the Mechanism of Action of IO Monotherapies and Combinations More Effectively

  • Understanding the role of in vivo and in vitro systems in translating IO therapeutics more effectively
  • Handling the unexpected: preclinical case studies detailing unpredictable outcomes
  • Overcoming key challenges in modelling combination immunotherapies

Barbara Joyce-Shaikh, Associate Principal Scientist, Merck

12.00 Lunch & Networking

T Cells and Beyond – Investigating the True Value of the ‘Next Generation’ of Checkpoint Modulators

13.00 The Role of TIM-3 in Myeloid Biology

  • Though initially described as a T cell checkpoint, emerging data points to a key role for TIM-3 expression on myeloid cells
  • Investigating a key subset of TIM-3 expressing dendritic cells
  • Understanding the part these targets play in the broader immune response and how they can be exploited most effectively through rational combination approaches

Catherine Sabatos-Peyton, Director, Novartis

13.30 Targeting the Adenosine Pathway to Unleash Potent Immune Responses in the Tumor Microenvironment

  • Outlining the scientific rationale behind targeting the adenosine pathway
  • Sharing key findings from the progression of A2R antagonist and anti-CD73 small molecule therapeutics
  • Investigating potential combinations involving adenosine-targeting approaches

Tim Sullivan, VP, Business Development, Arcus Biosciences

Understanding the Developmental Stories Behind Successful Clinical Candidates

11.00 BGB-A317, a Late Clinical Stage Anti-PD-1 Antibody with an Engineered Fc Domain

  • BGB-A317 is a humanized IgG4 mAb with high affinity and binding specificity against PD-1
  • BGB-A317 was specifically engineered to minimize binding to FcyR on macrophages, abrogating antibodydependent phagocytosis, a potential mechanism of T-cell clearance
  • Over 600 patients, representing a variety of tumor types, have received monotherapy BGB-A317

Amy Peterson, CMO, Immuno-Oncology, BeiGene

11.30 Novel Immuno-Oncology Trial Designs to Improve Kidney Cancer Therapy

  • Interrogating key IO trials that have defined this space – what can we learn from successes and failures?
  • Highlighting approaches to improve the design of IO clinical trials
  • Evaluating patient selection approaches
  • Assessing and validating novel immunotherapy endpoints

David McDermott, Professor of Medicine, Harvard Medical School

12.00 Lunch & Networking

Laying the Foundations for Robust and Safe Clinical Development

13.00 Immunogenicity Challenges & Considerations for I-O Therapies

  • All biologics have the potential to elicit an immune response
  • MOA of IO therapies complicate anti drug immunogenicity
  • Preclinical immunogenicity strategies to can reduce clinical development risk for IO therapies

Jochem Gokemeijer, Associate Director, Molecular Discovery Technologies, Bristol-Myers Squibb

13.30 Relating Non-Clinical Safety Considerations for IO Therapeutics to the Clinic

  • Non-clinical weight of evidence approaches to support combination clinical studies
  • Understanding limitations of current non-clinical models for cancer immunotherapy
  • Various approaches for first in human dose selection

Rodney Prell, Senior Scientist/Toxicologist, Cancer Immunotherapy Area Lead, Genentech

14.00
Afternoon Refreshments & Networking

Establishing Effective Immuno-Oncology Strategies to Maximize the Efficacy of Established and Novel Checkpoint Pathways

14.30
Enhancing Anti-Tumor Activity with M7824, a Novel Bifunctional Fusion Protein Targeting PD-L1 and TGF-β

  • Yan Lan Senior Director, Translational Immunology, EMD Serono

Synopsis

  • Rationale behind simultaneously targeting PD-L1 and TGF-β using a bifunctional immunotherapeutic
  • Enhanced antitumor efficacy and unique immunophenotypic signature of M7824 in preclinical models
  • M7824 as a combination partner

15.00
Targeting the CD47 “Do Not Eat” Signal With TTI-621 (SIRPa-IgG1 Fc)

Synopsis

  • Understanding the rationale behind targeting CD47
  • Presenting data from clinical studies of the CD47 blocking agent TTI-621 (SIRPa-IgG1 Fc)
  • Discussing combination opportunities involving CD47 blockade

15.30
Chair’s Closing Remarks

  • Bernard Fox Harder Family Endowed Chair for Cancer Research, Member and Chief, Molecular and Tumor Immunology, Providence Cancer Center